Bazinet A, Kadia T. Changing paradigms in the treatment of acute myeloid leukemia in older patients. Clin Adv Hematol Oncol. 2022;20(1):37–46.

PubMed  Google Scholar 

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.

Article  PubMed  Google Scholar 

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33.

Article  PubMed  Google Scholar 

Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2017. National Cancer Institute. https://seer.cancer.gov/csr/1975_2017/. Accessed 30 April 2022

Klepin H, Estey E, Kadia T. More versus less therapy for older adults with acute myeloid leukemia: new perspectives on an old debate. Am Soc Clin Oncol Educ Book. 2019;39:421–32.

Article  PubMed  Google Scholar 

Klepin HD. Geriatric perspective: how to assess fitness for chemotherapy in acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2014;2014(1):8–13.

Article  PubMed  Google Scholar 

Ofran Y, Tallman MS, Rowe JM. How I treat acute myeloid leukemia presenting with preexisting comorbidities. Blood. 2016;128(4):488–96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bansal N, Adams MJ, Ganatra S, et al. Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors. Cardio-Oncology. 2019;5:18. https://doi.org/10.1186/s40959-019-0054-5.

Article  PubMed  PubMed Central  Google Scholar 

Neuendorff NR, Loh KP, Mims AS, Christofyllakis K, Soo WK, Bölükbasi B, Oñoro-Algar C, Hundley WG, Klepin HD. Anthracycline-related cardiotoxicity in older patients with acute myeloid leukemia: a Young SIOG review paper. Blood Adv. 2020;4(4):762–75. https://doi.org/10.1182/bloodadvances.2019000955.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Doolub G, Mamas MA. Percutaneous coronary angioplasty in patients with cancer: clinical challenges and management strategies. J Pers Med. 2022;12(9):1372. https://doi.org/10.3390/jpm12091372.

Article  PubMed  PubMed Central  Google Scholar 

Ozga M, Huang Y, Blachly JS, Grieselhuber NR, Wall S, Larkin K, Haque T, Walker AR, Bhatnagar B, Behbehani G, Vasu S, Maakaron JE, Lustberg M, Mims AS. The incidence of invasive fungal infections in patients with AML treated with a hypomethylating agent. Clin Lymphoma Myeloma Leuk. 2021;21(1):e76–83. https://doi.org/10.1016/j.clml.2020.08.013.

Article  CAS  PubMed  Google Scholar 

Litvin R, Dasgupta M, Saad Eldin M, Shah M, Fakhran S. Azacitidine-induced pneumonitis in a patient with acute myeloid leukemia and hyperleukocytosis. Cureus. 2022;14(7):e26758. https://doi.org/10.7759/cureus.26758.

Article  PubMed  PubMed Central  Google Scholar 

Forghieri F, Luppi M, Morselli M, Potenza L. Cytarabine-related lung infiltrates on high resolution computerized tomography: a possible complication with benign outcome in leukemic patients. Haematologica. 2007;92(9):e85–90. https://doi.org/10.3324/haematol.11697.

Article  CAS  PubMed  Google Scholar 

Quintás-Cardama A, Ravandi F, Liu-Dumlao T, Brandt M, Faderl S, Pierce S, et al. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood. 2012;120(24):4840–5.

Article  PubMed  PubMed Central  Google Scholar 

Vachhani P, Al Yacoub R, Miller A, Zhang F, Cronin TL, Ontiveros EP, et al. Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: a single center experience. Leuk Res. 2018;12(75):29–35.

Article  Google Scholar 

Kadia TM, Wei AH. Evolution of therapy for older patients with acute myeloid leukemia. Cancer J. 2022;28(1):67–72.

Article  PubMed  PubMed Central  Google Scholar 

Itzykson R, Fournier E, Berthon C, Röllig C, Braun T, Marceau-Renaut A, et al. Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. Blood. 2021;138(7):507–19.

Article  CAS  PubMed  Google Scholar 

Sorror ML, Storer BE, Fathi AT, Brunner A, Gerds AT, Sekeres MA, et al. Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia. Blood. 2021;138(5):387–400.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106–17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

•• DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–29. Evolution of therapy for older patients with acute myeloid leukemia. Confirmed the survival benefit of venetoclax combined with AZA compared to AZA alone.

Article  CAS  PubMed  Google Scholar 

Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kadia TM, Reville PK, Wang X, et al. Phase II study of venetoclax added to cladribine plus low-dose cytarabine alternating with 5-azacitidine in older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2022;40(33):3848–57.

Article  CAS  PubMed  Google Scholar 

Kim K, Maiti A, Loghavi S, Pourebrahim R, Kadia TM, Rausch CR, et al. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. Cancer. 2021;127(20):3772–81.

Article  CAS  PubMed  Google Scholar 

Venugopal S, Shoukier M, Konopleva M, Dinardo CD, Ravandi F, Short NJ, Andreeff M, Borthakur G, Daver N, Pemmaraju N, Sasaki K, Montalban-Bravo G, Marx KR, Pierce S, Popat UR, Shpall EJ, Kanagal-Shamanna R, Garcia-Manero G, Kantarjian HM, Kadia TM. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy. Cancer. 2021;127(19):3541–51. https://doi.org/10.1002/cncr.33675.

Article  CAS  PubMed  Google Scholar 

Aprea therapeutics announces results of primary endpoint from phase 3 trial of eprenetapopt in TP53 mutant myelodysplastic syndromes (MDS) [press release]. https://ir.aprea.com/news-releases/news-release-details/aprea-therapeutics-announces-results-primary-endpoint-phase-3. 2020. Accessed 30 April 2022.

Sallman D, Asch A, Kambhampati S, et al. The first-in-class anti-CD47 antibody magrolimab combined with azacitidine is well-tolerated and effective in AML patients: phase 1b results. Blood. 2020;136(suppl 1):330.

Google Scholar 

•• Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454–64. Confirmed the addition of midostaurin to standard IC improved survival in patients with FLT3-mutated AML.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reville PK, Sasaki K, Kantarjian HM, et al. Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: revisiting the European LeukemiaNet adverse risk classification. Am J Hematol. 2022;97(3):329–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schlenk RF, Weber D, Fiedler W, Salih HR, Wulf G, Salwender H, et al. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood. 2019;133(8):840–51.

Article  CAS  PubMed  Google Scholar 

• Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728–40. Showed that single-agent gilteritinib was associated with superior response rates and OS compared to standard salvage therapy in the R/R FLT3-mutated AML setting.

Article  CAS  PubMed  Google Scholar 

Ohanian M, Garcia-Manero G, Levis M, Jabbour E, Daver N, Borthakur G, et al. Sorafenib combined with 5-azacytidine in older patients with untreated FLT3-ITD mutated acute myeloid leukemia. Am J Hematol. 2018;93(9):1136–41.

Article  CAS  PubMed  Google Scholar 

Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013;121(23):4655–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Esteve J, Schots R, Bernal Del Castillo T, Lee J, Wang ES, Dinner S, et al. Multicenter, open-label, 3-arm study of gilteritinib, gilteritinib plus azacitidine, or azacitidine alone in newly diagnosed FLT3 mutated (FLT3mut+) acute myeloid leukemia (AML) patients ineligible for intensive induction chemotherapy: findings from the safety cohort. Blood. 2018;132(Supplement 1):2736.

Article  Google Scholar 

Sallman DA, Asch AS, Al Malki MM, Lee DJ, Donnellan WB, Marcucci G, et al. The first-in-class anti-CD47 antibody magrolimab (5F9) in combination with azacitidine is effective in MDS and AML patients: ongoing phase 1b results. Blood. 2019;134(Supplement_1):569.

Article  Google Scholar 

Short NJ, DiNardo CD, Daver N, Nguyen D, Yilmaz M, Kadia TM, Garcia-Manero G, Issa GC, Huang X, Qiao W, Sasaki K, Montalban-Bravo G, Chien KS, Borthakur G, Delumpa R, Milton A, Pierce SA, Jabbour EJ, Konopleva M, Kantarjian H. Farhad Ravandi; A triplet combination of azacitidine, venetoclax and gilteritinib for patients with FLT3-mutated acute myeloid leukemia: results from a phase I/II study. Blood. 2021;138(Supplement 1):696. https://doi.org/10.1182/blood-2021-153571.

Article  Google Scholar 

Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739–44.

Article  CAS